Evidence map›Paper›PMID 40944713›Full record

ArticleCancer immunology, immunotherapy : CII2025

High-plex imaging of hepatoblastoma and adjacent liver in pediatric patients reveals a predominant myeloid infiltrate expressing immune-checkpoints.

Daniëlle Krijgsman, Stephanie A Schubert, Lianne J Kraaier, Yuyan Lu, Kristof van Avondt, Meggy E L Verdonschot, Jeanette H W Leusen, Marius C van den Heuvel, Ruben H de Kleine, Vincent E de Meijer and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Daniëlle Krijgsman *Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University, 3584 CX, Utrecht, The Netherlands. d.krijgsman-4@umcutrecht.nl.
Stephanie A Schubert *Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
Lianne J KraaierPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
Yuyan LuPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
Kristof van AvondtCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht University, 3584 CX, Utrecht, The Netherlands.
Meggy E L VerdonschotCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht University, 3584 CX, Utrecht, The Netherlands.
Jeanette H W LeusenCenter for Translational Immunology, University Medical Center, 3584 CX, Utrecht, The Netherlands.
Marius C van den HeuvelDepartment of Pathology and Medical Biology, University Medical Center Groningen, 9713 GZ, Groningen, The Netherlands.
Ruben H de KleineDepartment of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University of Groningen, University Medical Center Groningen, 9713 GZ, Groningen, The Netherlands.
Vincent E de MeijerDepartment of Surgery, Section of Hepatobiliary Surgery and Liver Transplantation, University of Groningen, University Medical Center Groningen, 9713 GZ, Groningen, The Netherlands.
Kathelijne C J KraalPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
Ronald R de KrijgerPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
József ZsirosPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
Weng Chuan Peng *Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. W.C.Peng@prinsesmaximacentrum.nl.
Yvonne Vercoulen *Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University, 3584 CX, Utrecht, The Netherlands. Y.Vercoulen@umcutrecht.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsHepatoblastoma (HB) is a rare form of pediatric liver cancer currently treated with chemotherapy, which has major side effects, and surgery. We aimed to characterize the immune landscape of HB to improve our understanding of the immunologic contribution to this disease and explore immunotherapeutic options.

methodsTo investigate the tissue landscape, a high-plex imaging mass cytometry panel was developed and applied to tissue of treatment-naïve HB and chemotherapy-treated HB, with paired adjacent normal liver tissue. Moreover, immunofluorescence was used to stain HB and normal liver tissue for the Kupffer cell marker MARCO, macrophage markers CD68 and CD163, T cell marker CD8, and immune checkpoints VISTA and SIRPα. A public single-cell RNA sequencing (scRNA-seq) dataset was analyzed consisting of chemotherapy-treated HB and paired normal liver tissue.

resultsNormal liver tissue showed a compartmentalized immune landscape between the portal triad area and liver parenchyma. HB showed a heterogeneous immune landscape predominantly comprising CD68

conclusionsThe absence of immune checkpoints and exhaustion markers in CD8

Indexed as

HepatoblastomaImmune Checkpoint ProteinsLiverLiver NeoplasmsMyeloid CellsCD163 AntigenChildChild, PreschoolFemaleHumansInfantMacrophagesMaleReceptors, ImmunologicCD163 AntigenImmune Checkpoint ProteinsReceptors, ImmunologicImaging mass cytometryImmune checkpointsKupffer cellsSingle-cell RNA sequencingT cells

Identifiers

PMID40944713
PMCPMC12433390

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.